References
- Moayyedi P. The epidemiology of obesity and gastrointestinal and other diseases: an overview. Dig. Dis. Sci.53(9), 2293–2299 (2008).
- Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med.142(7), 525–531 (2005).
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature402(6762), 656–660 (1999).
- Cone RD, Cowley MA, Butler AA, Fan W, Marks DL, Low MJ. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int. J. Obes. Relat. Metab. Disord.25(Suppl. 5), S63–S67 (2001).
- Wren AM, Seal LJ, Cohen MA et al. Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab.86(12), 5992 (2001).
- Dornonville De La Cour C, Lindqvist A, Egecioglu E et al. Ghrelin treatment reverses the reduction in weight gain and body fat in gastrectomised mice. Gut54(7), 907–913 (2005).
- Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature407(6806), 908–913 (2000).
- Wortley KE, Anderson KD, Garcia K et al. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc. Natl Acad. Sci. USA101(21), 8227–8232 (2004).
- Cummings DE, Weigle DS, Frayo RS et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. J. Med.346(21), 1623–1630 (2002).
- Monteiro MP, Ribeiro AH, Nunes AF et al. Increase in ghrelin levels after weight loss in obese Zucker rats is prevented by gastric banding. Obes. Surg.17(12), 1599–1607 (2007).
- Lu SC, Xu J, Chinookoswong N et al. An acyl-ghrelin-specific neutralizing antibody inhibits the acute ghrelin-mediated orexigenic effects in mice. Mol. Pharmacol.75(4), 901–907 (2009).
- Mayorov AV, Amara N, Chang JY et al. Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice. Proc. Natl Acad. Sci. USA105(45), 17487–17492 (2008).
- Esler WP, Rudolph J, Claus TH et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology148(11), 5175–5185 (2007).
- Zorrilla EP, Iwasaki S, Moss JA et al. Vaccination against weight gain. Proc. Natl Acad. Sci. USA103(35), 13226–13231 (2006).
- Vizcarra JA, Kirby JD, Kim SK, Galyean ML. Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs. Domest. Anim. Endocrinol.33(2), 176–189 (2007).
- Brown MJ. Therapeutic potential of vaccines in the management of hypertension. Drugs68(18), 2557–2560 (2008).
- Lechner F, Jegerlehner A, Tissot AC et al. Virus-like particles as a modular system for novel vaccines. Intervirology45(4–6), 212–217 (2002).
- Ghosh MK, Borca MV, Roy P. Virus-derived tubular structure displaying foreign sequences on the surface elicit CD4+ Th cell and protective humoral responses. Virology302(2), 383–392 (2002).
- Andrade S, Carreira M, Ribeiro A. Development of an anti-gherelin vaccine for obesity treatment. Endocr. Rev.32(03), (2011).
- Goldstone AP, Thomas EL, Brynes AE et al. Elevated fasting plasma ghrelin in Prader-Willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance. J. Clin. Endocrinol. Metab.89(4), 1718–1726 (2004).